FILAMENT HEALTH ANNOUNCES SHIPMENT OF BOTANICAL PSILOCYBIN TO THE UNIVERSITY OF WISCONSIN-MADISON

UW-Madison, a globally recognized psychiatric research institution, will study Filament's botanical psilocybin drug candidate, PEX010, in two clinical trials exploring neuroplasticity

VANCOUVER, BC, Jan. 21, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that it has shipped its botanical psilocybin drug candidate, PEX010, to the University of Wisconsin–Madison (UW–Madison) for investigation in two clinical trials. Both trials are United States Food and Drug Administration (FDA)-authorized and will study the effects of psilocybin on neuroplasticity.

"Our goal with this research is to examine how psilocybin's effects on neuroplasticity may impact participants' wellbeing and their ability to understand the world around them," said Charles L. Raison, MD, principal investigator of both clinical trials and professor of psychiatry at the University of Wisconsin School of Medicine and Public Health in Madison, Wis.

Research has shown that psilocybin can improve neuroplasticity — the brain's ability to reorganize and form new neural connections — which may contribute to psilocybin's therapeutic effects. At UW–Madison, the first clinical trial studying PEX010, titled The ENHANCE Study, is being funded by the Tiny Blue Dot Foundation.

Tiny Blue Dot Foundation is dedicated to advancing scientific research to help individuals understand the concept of Perception Box™, a metaphor, developed by Founder Elizabeth R. Koch which represents the internal beliefs, experiences, and biases that shape how individuals view the world and engage with others. By expanding these boundaries, individuals can reduce suffering, foster greater self-acceptance and empathy for others, and reframe trauma or challenges as opportunities for personal growth.

The ENHANCE Study will dose 100 healthy volunteers to examine whether strategies that enhance psychedelic-induced neuroplasticity and increase the long-term salience of the psychedelic experience may also enhance the ability of psychedelics to support long-term enlargement of the Perception Box.

The second clinical trial, titled The RECAP2 Study, will examine the proposition that the neuroplastic effects of psychedelics such as psilocybin underlie their long-term effects on wellbeing. This premise will be investigated in a cohort of 60 physically healthy volunteers with slight decline in wellbeing.

"The University of Wisconsin–Madison is an internationally recognized leader in psychiatric research," said Benjamin Lightburn, Chief Executive Officer and Co-Founder of Filament Health. "We are proud that Dr. Raison and his team have selected Filament's drug candidate for clinical trials of this calibre and we're pleased to support their important research."

Both clinical trials at UW–Madison are expected to begin dosing in Q1 2025. PEX010 is authorized for investigation in 41 clinical trials worldwide for 14 mental health indications.

ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (CBOE CA:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.

Learn more at www.filament.health and on Twitter, Instagram, and LinkedIn.

FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including status of patent applications and the ability to secure patents. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐ looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.

SOURCE Filament Health Corp.

MEDIA RELATIONS: Anna Cordon, Vice President, Marketing & Communications, [email protected]; INVESTOR RELATIONS, [email protected]